Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial
Trial demonstrates that iberdomide with daratumumab and dexamethasone improves MRD negativity in newly diagnosed multiple myeloma patients, suggesting immune system involvement.
Key Points
This research aims to evaluate the impact of iberdomide treatment on MRD negativity and immune dynamics in transplant-ineligible newly diagnosed multiple myeloma patients.
Phase 1/2 CC-220-MM-001 trial with patients who had newly diagnosed multiple myeloma.
Patients received iberdomide, daratumumab, and dexamethasone and were assessed for MRD negativity rates.
Immune changes were evaluated through flow cytometry and serum free light chains assessment.
44% of patients achieved MRD-negative complete response at any time during treatment.
Median time to MRD negativity was 12.0 months, with 63.6% sustaining MRD negativity at 12 months.
Higher baseline CD3+, CD8+, and Treg populations were associated with MRD-negative CR status.